ALK and Ewing sarcoma: Ewing sarcoma sample zccs227 showed differential sensitivity to a number of chemotherapeutic agents including doxorubicin, irinotecan and vincristine as well as targeted agents affecting PI3K pathway, receptor tyrosine kinase (ALK) and cell cycle (AURKA) signalling pathways (Fig. 6F).